SARS-CoV-2 spike protein receptor-binding domain (RBD) epitope A (SARS-CoV-2 RBD Epitope A)

The SARS-CoV-2 Spike protein receptor-binding domain (RBD) epitope A is a critical antigenic site located within the receptor-binding motif (RBM) of the viral spike glycoprotein [UniProt P0DTC2]. This epitope is the primary target for many potent neutralizing antibodies because it directly overlaps with the binding footprint of the human angiotensin-converting enzyme 2 (ACE2) receptor [Barnes et al., 2020, Nature]. By binding to Epitope A, therapeutic antibodies and vaccine-induced antibodies sterically hinder the interaction between the virus and the host cell, effectively preventing viral attachment and subsequent entry [Yuan et al., 2020, Science]. However, this region is highly plastic and frequently accumulates mutations, such as those seen in the Alpha, Beta, and Omicron variants, which can lead to immune evasion and a significant reduction in the efficacy of monoclonal antibody treatments [Harvey et al., 2021, Nature Reviews Microbiology]. Understanding the structural and mutational landscape of Epitope A is essential for the ongoing development of next-generation vaccines and antibody cocktails designed to maintain broad-spectrum activity against evolving SARS-CoV-2 strains [Krammer, 2020, Nature].

Other names

Class 1 RBD epitopeReceptor-binding motif (RBM) epitopeACE2-competing epitopeRBD Site ASARS-CoV-2 S-RBD Epitope A

Neutralization of viral entry by sterically blocking the interaction between the viral receptor-binding domain (RBD) and the host cell receptor, angiotensin-converting enzyme 2 (ACE2) [Barnes et al., 2020, Nature; FDA Fact Sheet for Bamlanivimab].